Medicare Enrolled

Dr. Adnan Peer, MD

Rheumatology · Houston, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
17045 SAINT EDWARDS DR STE 110, Houston, TX 77090
2813979198
In practice since 2007 (18 years)
NPI: 1962693150 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Peer from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Peer? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Peer

Dr. Adnan Peer is a rheumatology in Houston, TX, with 18 years in practice. Based on federal Medicare data, Dr. Peer performed 90,475 Medicare services across 647 unique beneficiaries.

Between the years covered by Open Payments, Dr. Peer received a total of $44,008 from 51 pharmaceutical and/or device companies across 1364 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Peer is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 18 years in practice▲ Top 17% volume in TX$ $44,008 industry payments

Medicare Practice Summary

Medicare Utilization ↗
90,475
Medicare services
Top 17% in TX for rheumatology
647
Unique beneficiaries
$5
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~5,026 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Certolizumab injection (Cimzia)86,000$4$10
Extended-release steroid injection (Zilretta)1,568$13$25
Denosumab injection (Prolia/Xgeva)1,140$19$30
Office visit, established patient (30-39 min)475$91$200
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle466$57$150
Aspiration and/or injection of fluid large joint using ultrasound guidance129$103$242
Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose104$58$100
Blood draw (venipuncture)85$8$10
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less85$52$250
Injection, methylprednisolone acetate, 40 mg62$6$35
Injection, zoledronic acid, 1 mg57$7$114
Limited ultrasound scan of joint or other extremity structure except blood vessels50$34$60
New patient office visit (45-59 min)46$112$300
Office visit, established patient (20-29 min)44$60$100
Influenza vaccine, quadrivalent, 0.5 ml dosage33$20$50
Flu vaccine administration32$31$50
Bone density scan (DEXA)27$39$100
Injection, methylprednisolone acetate, 80 mg22$9$35
Ultrasonic guidance for needle placement17$46$75
Drug injection, under skin or into muscle17$10$30
Injection of carpal tunnel16$68$99
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
0.1% high complexity
99.1% medium
0.8% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$44,008
Total received (2018-2024)
Avg $6,287/year across 7 years
Top 11% in TX for rheumatology
51
Companies
1,364
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$24,583 (55.9%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$16,416 (37.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$3,009 (6.8%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$4,363
2023
$10,121
2022
$3,899
2021
$3,068
2020
$2,260
2019
$12,019
2018
$8,278

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$5,947
Novartis Pharmaceuticals Corporation
$5,719
GlaxoSmithKline, LLC.
$4,832
Amgen Inc.
$4,804
Horizon Therapeutics plc
$4,056
UCB, Inc.
$2,596
Celgene Corporation
$1,827
ABBVIE INC.
$1,825
Janssen Biotech, Inc.
$1,372
Fresenius Kabi USA, LLC
$1,249
PFIZER INC.
$1,247
Mallinckrodt Hospital Products Inc.
$947
AbbVie Inc.
$837
E.R. Squibb & Sons, L.L.C.
$735
AbbVie, Inc.
$675
GENZYME CORPORATION
$599
Radius Health, Inc.
$464
Aurinia Pharma U.S., Inc.
$464
Lilly USA, LLC
$446
Genentech USA, Inc.
$420
West-Ward Pharmaceuticals
$309
Mallinckrodt Enterprises LLC
$284
Horizon Pharma plc
$237
Johnson & Johnson Health Care Systems Inc.
$231
Sandoz Inc.
$179
McKesson Specialty Care Distribution, LLC
$174
Alexion Pharmaceuticals, Inc.
$162
Actelion Pharmaceuticals US, Inc.
$127
TerSera Therapeutics LLC
$122
Boehringer Ingelheim Pharmaceuticals, Inc.
$110
ANI Pharmaceuticals, Inc.
$105
Cardinal Health 110 LLC
$100
Janssen Scientific Affairs, LLC
$80
Antares Pharma, Inc.
$77
Mallinckrodt LLC
$72
Biosense Webster, Inc.
$68
Hikma Pharmaceuticals USA
$66
Kyowa Kirin, Inc.
$62
SANOFI-AVENTIS U.S. LLC
$54
Mylan Institutional Inc.
$50
Biocon Biologics Inc
$36
Fidia Pharma USA Inc.
$33
IDORSIA PHARMACEUTICALS US INC
$32
Pacira Pharmaceuticals Incorporated
$30
Alvogen Inc
$24
Kiniksa Pharmaceuticals, Ltd.
$24
Phadia US Inc.
$23
MEDAC PHARMA, INC.
$23
Shield Therapeutics Inc
$22
SCILEX PHARMACEUTICALS INC.
$16
DePuy Synthes Sales Inc.
$14
Top 3 companies account for 37.5% of total payments
Associated products mentioned in payments ›
ACCRUFER · ACTHAR · AMJEVITA · AVSOLA · Actemra · Arcalyst · BENLYSTA · Bimzelx · CARTO 3 · COSENTYX · CYLTEZO · Cimzia · Crysvita · EVENITY · EVUSHELD · Enbrel · FORTEO · HUMIRA · HYALGAN · HYRIMOZ · Hulio · Humira · IDACIO · ImmunoCAP · Iovera · KEVZARA · KRYSTEXXA · LUPKYNIS · LYRICA · MONOVISC · Mitigare · Neupro · OFEV · ORENCIA · OTREXUP · Otezla · Otrexup · PENNSAID · PURIFIED CORTROPHIN GEL · Prolia · QUVIVIQ · Quzyttir · RAYOS · REMICADE · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SIMPONI · SIMPONI ARIA · SKYRIZI · STELARA · STRENSIQ · Strensiq · TALTZ · TAVNEOS · TERIPARATIDE · TREMFYA · Tavneos · Tymlos · UPTRAVI · XELJANZ · ZTLido
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (56%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $49 per 100 Medicare services performed
Looking for a rheumatology in Houston?
Compare rheumatologys in the Houston area by procedure volume, costs, and industry payment transparency.
Browse rheumatologys nearby

Geographic Context

Rheumatologys within 10 mi
76
Per 100K population
1.6
County median income
$73,104
Nearest hospital
HCA HOUSTON HEALTHCARE NORTHWEST
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Peer is a mixed practice specialist, with above-average Medicare volume (top 17% in TX), and high industry engagement (low-engagement, top 11%), with 18 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Peer experienced with certolizumab injection (cimzia)?
Based on Medicare claims data, Dr. Peer performed 86,000 certolizumab injection (cimzia) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Peer receive payments from pharmaceutical companies?
Yes. Dr. Peer received a total of $44,008 from 51 companies across 1,364 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Peer's costs compare to other rheumatologys in Houston?
Dr. Peer's average Medicare payment per service is $5. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Peer) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →